Over the coming five years, the digital transformation of clinical trials will accelerate, as the sector has largely completed its initial shift from paper-based trial processes to electronic data capture. Given the mandates for the incorporation of precision medicine, personalization and real-world evidence into discovery and human trials, as well as the integration of advanced technologies as the therapies, it is incumbent upon contract research organizations (CROs) and other key stakeholders to shift their focus to the tools and platforms of the future. A failure to recognize and respond to rapidly accelerating trends will leave organizations at a disadvantage in terms of their relevance and ability to support the next generation of clinical trials.